ENTITY
Xiamen Amoytop Biotech Co Ltd

Xiamen Amoytop Biotech Co Ltd (688278 CH)

37
Analysis
Health Care • China
Xiamen Amoytop Biotech Co., Ltd. operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products. Xiamen Amoytop Biotech markets its products primarily throughout China with limited overseas.
more
•26 Feb 2025 05:24

STAR50/STAR100 Index Rebalance Preview: One Is Meh; The Other Is👍

Over the last 3 weeks, the outright adds to the STAR50 and STAR100 indices have underperformed the outright deletes by 6.36% in both cases....

Logo
1.5k Views
Share
•25 Feb 2025 14:21

Quiddity Leaderboard STAR 50/100 Mar 25: LONGs Up ~12% Vs SHORTs in a Month; More to Come

The STAR50/100 March 2025 index review results will be announced in a few days. Our final expectations for index changes can be found in this...

Logo
1.4k Views
Share
•13 Jan 2025 05:50

STAR50/STAR100 Index Rebalance Preview: Migrations & Outright Changes Lead to Outperformance

There could be 16 changes across the STAR50/100 in March with passives trading nearly US$2bn round-trip. The forecast adds have outperformed the...

Logo
914 Views
Share
•19 Dec 2024 18:27

Quiddity Leaderboard STAR 50/100 Mar25: Multiple Changes, Large Flows; High-Impact Trade Idea

We believe the STAR 50 expected ADDs could continue to outperform the STAR 50 expected DELs over the next few weeks. All of these names have 3.5x...

Share
•05 Nov 2024 13:29

Quiddity Leaderboard STAR 50/100 Dec 24: Four Changes Possible for STAR 100

For the STAR 100 rebalance, we estimate one-way flow to be around US$130mn. The expected ADDs/DELs have around 0.6x-2.3x ADV to trade. We expect...

Share
x